A lab-made “molecular glue” reprograms a lymphoma oncogene to trigger cancer-cell self-destruction, in early cell and mouse studies

Evidence stage: PreclinicalRegulatory status: InvestigationalGuideline status: Not addressed

Important context

  • Not yet peer-reviewed: This record's primary source is a preprint that has not completed formal peer review as of the last_reviewed date above.

Researchers at Stanford University, led by developmental biologist Gerald Crabtree and chemical biologist Nathanael Gray, engineered a synthetic small-molecule compound (a “KAT-TCIP,” short for lysine acetyltransferase-based transcriptional chemical inducer of proximity) that physically tethers the oncogenic protein BCL6 — a transcription factor that keeps diffuse large B-cell lymphoma (DLBCL) cells alive by silencing their own cell-death genes, and that is dysregulated in roughly 40% of DLBCL cases — to CDK9, a separate enzyme that switches genes on. This forced proximity flips BCL6’s normal function, redirecting it to switch on the very apoptosis (programmed cell-death) genes it normally represses. Because BCL6 is expressed almost exclusively in this lymphoma cell type and one specific normal B-cell population, the compound was highly selective in laboratory testing: it killed only diffuse large B-cell lymphoma cells among 859 different cancer cell lines tested (cell-proliferation IC50 approximately 0.8 nanomolar), and eliminated tumors within 11 days in DLBCL cell-line-derived mouse xenograft models. This work is reported in a preprint (bioRxiv, DOI 10.1101/2025.03.14.643404, PMID 40166243) that has not yet completed formal peer review as of this record; it is laboratory (cell-line) and animal (mouse) research only — no human patients have been treated with this compound, and it is not a clinical trial or an approved or investigational human therapy of any kind.

What This Means

In laboratory cell-line and mouse studies, a Stanford-engineered small molecule that forces two proteins (the lymphoma oncogene BCL6 and the enzyme CDK9) into physical proximity reprogrammed BCL6 to switch ON cell-death genes it normally switches off, killing diffuse large B-cell lymphoma cells with high potency and selectivity (killing only DLBCL cells among 859 cancer cell lines tested) and eliminating tumors within 11 days in mouse xenograft models.

What This Doesn't Mean

This is laboratory (cell-line) and animal (mouse) research only — it has NOT been tested in any human patient, is not a clinical trial, and is not an investigational or approved human therapy of any kind. Results in mouse models frequently do not translate to human patients; this compound would need to clear additional preclinical safety work and then multiple phases of human clinical trials before it could become an actual treatment, if it ever does.

Why It Matters

A highly selective, mechanistically novel approach to lymphoma cell death — reprogramming an oncogene's own function rather than simply blocking it — represents genuine, real basic-science progress worth tracking early, consistent with this site's mission of showing the full research pipeline, not only approved drugs.

Promise & Proof

Proof — strength of the evidence 1 / 5
  • Base score from evidence stage: Preclinical.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • An early-stage finding (preclinical or early human) that already shows at least one concrete signal of significance above.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Laboratory cell-line panels (including 859 distinct cancer cell lines used to test selectivity) and mouse xenograft models of diffuse large B-cell lymphoma (DLBCL) — no human patients have been treated with this compound. (Unspecified)

Not an available or investigational treatment for any patient. This record deliberately shows an EARLY-stage, preclinical discovery alongside packet 2's FDA-approved lymphoma therapy, to give readers an honest picture of how far this kind of laboratory finding still has to go before it could become a real treatment option.

Full evidence details
Study design
Laboratory (preclinical)

Funding & Conflicts

Reported academic/institutional origin (Stanford University, Crabtree and Gray laboratories) — not independently confirmed against a primary grant-disclosure document.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

A lab-made “molecular glue” reprograms a lymphoma oncogene to trigger cancer-cell self-destruction, in early cell and mouse studies

https://cancerdiscoveries.com/discoveries/a-lab-made-molecular-glue-reprograms-a-lymphoma-oncogene-to-trigger-cancer-cell-self-destruction-in-early-cell-and-mouse-studies/

Evidence stage: Preclinical

What This Means

In laboratory cell-line and mouse studies, a Stanford-engineered small molecule that forces two proteins (the lymphoma oncogene BCL6 and the enzyme CDK9) into physical proximity reprogrammed BCL6 to switch ON cell-death genes it normally switches off, killing diffuse large B-cell lymphoma cells with high potency and selectivity (killing only DLBCL cells among 859 cancer cell lines tested) and eliminating tumors within 11 days in mouse xenograft models.

What This Doesn't Mean

This is laboratory (cell-line) and animal (mouse) research only — it has NOT been tested in any human patient, is not a clinical trial, and is not an investigational or approved human therapy of any kind. Results in mouse models frequently do not translate to human patients; this compound would need to clear additional preclinical safety work and then multiple phases of human clinical trials before it could become an actual treatment, if it ever does.

Why It Matters

A highly selective, mechanistically novel approach to lymphoma cell death — reprogramming an oncogene's own function rather than simply blocking it — represents genuine, real basic-science progress worth tracking early, consistent with this site's mission of showing the full research pipeline, not only approved drugs.

Important Limitations

  • This record's primary source is a preprint that has not completed formal peer review as of the last_reviewed date above.

Primary sources

  • A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-Induced Cell Death (bioRxiv preprint) — https://doi.org/10.1101/2025.03.14.643404 (DOI 10.1101/2025.03.14.643404, PMID 40166243)

Date verified: 2026-08-13

Correction status: No correction or retraction